|
Osteoporosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interleukin-6 (IL-6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on bone cells and has been implicated in the pathogenesis of osteoporosis.
|
10865225 |
2000 |
|
Osteoporosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interleukin 6 (IL-6) is a multifunctional cytokine and a potent stimulator of bone resorption and has been implicated in the pathogenesis of osteoporosis in postmenopausal women.
|
14997289 |
2004 |
|
Osteoporosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interleukin-6 (IL-6) is produced by osteoblasts, and potently stimulates osteoclast activation playing a key role in normal bone resorption as well as in post-menopausal and inflammation-driven osteoporosis.
|
22999910 |
2013 |
|
Osteoporosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interleukin-6 Inhibitor Suppresses Hyperalgesia Without Improvement in Osteoporosis in a Mouse Pain Model of Osteoporosis.
|
30666355 |
2019 |
|
Osteoporosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interleukin-6 is negatively controlled by estrogens and androgens, and it plays a central role in the pathogenesis of the osteoporosis seen in conditions characterized by increased bone resorption, such as sex-steroid deficiency and hyperparathyroidism.
|
9441573 |
1998 |
|
Osteoporosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A single-nucleotide polymorphism (SNP) in the promoter region of the interleukin-6 (IL-6) gene at position -174 (G>C) has been reported to be associated with a variety of major diseases, such as Alzheimer disease, atherosclerosis, and cardiovascular disease, cancer, non-insulin-dependent diabetes mellitus, osteoporosis, sepsis, and systemic-onset juvenile chronic arthritis.
|
15364891 |
2004 |
|
Osteoporosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
As such, IL-6 polymorphisms are able to influence the risk of osteoporosis as well as other chronic disorders involving IL-6 activity.
|
12519862 |
2003 |
|
Osteoporosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Association between IL-6 polymorphism and clinical osteoporosis was evaluated by pooled odds ratios (ORs) and 95 % CIs.
|
23760743 |
2014 |
|
Osteoporosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
ATP-binding cassette transporters A1 and C6, peroxisome proliferator activated receptor alpha, interleukin-6); and (3) studies showing that multiple genes appear to be at the intersection of several age-related disorders such as cardiovascular disease, neurological disorders and osteoporosis (i.e. apolipoprotein E, vitamin D receptor, matrix Gla protein, peroxisome proliferator activated receptor gamma, angiotensin-converting enzyme, estrogen receptor, androgen receptor, methylenetetrahydrofolate reductase).
|
12544661 |
2003 |
|
Osteoporosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Besides VEGF, IL-6- or IL-8-targeted adjunctive therapy maybe a new strategy to improve the treatment of osteoporosis.
|
29934049 |
2019 |
|
Osteoporosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Compared to the normal BMD, the OR for increasing IL-6 level of decreasing BMD groups (osteoporosis and/or osteopaenia) was 9.50 (95% CI: 1.44-62.80).
|
30845341 |
2019 |
|
Osteoporosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Comparisons of interleukin-6 (IL-6), C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), indicators of osteoporosis [serum phosphate, serum calcium and bone mineral density (BMD)], content of 25(OH)D, serum sodium, serum potassium and BUN were conducted among groups.
|
30651805 |
2019 |
|
Osteoporosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cytokines such as IL-6 and TNF-α are suggested to play a role in bone resorption and, thus, in the etiology of osteoporosis.
|
30701344 |
2019 |
|
Osteoporosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Duration of diabetes mellitus (DM) and levels of glycosylated hemoglobin A1c (HbA1c), fasting plasma glucose (FPG) and fasting insulin (FINS) level, levels of C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-α) and interleukin 6 (IL-6), level of 24h urine protein (24hndb) of patients in the combination with osteoporosis group was significantly higher, while the value of eGFR was lower than that of patients in the non-combination with osteoporosis group.
|
30179212 |
2018 |
|
Osteoporosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Evidence suggested a role for genetic variation in IL6 and LRP5 in conferring risk for osteoporosis in Caucasian women, with the latter manifest only in smokers.
|
19506792 |
2010 |
|
Osteoporosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we investigated the roles of 2 polymorphisms mapping to the promoters of TGF-β1and IL-6 genes on the genetic susceptibility to osteoporosis as well as calcium and vitamin D levels.
|
29860063 |
2018 |
|
Osteoporosis
|
0.400 |
Biomarker
|
disease |
CTD_human |
Higher values of IL-6 were recorded in those with idiopathic osteoporosis than in controls (2.79 vs. 1.43; p<0.05).
|
15995586 |
2005 |
|
Osteoporosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, CXCL8 and CCL20 enhanced osteoblast-mediated osteoclastogenesis, partly via IL-6 production, suggesting that CXCL8 and CCL20 may contribute to osteoporosis in rheumatoid arthritis by affecting bone cell communication.
|
26103626 |
2015 |
|
Osteoporosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Increased IL-6 levels are also observed in several diseases, including rheumatoid arthritis (RA), systemic-onset juvenile chronic arthritis (JCA), osteoporosis, and psoriasis.
|
12220549 |
2003 |
|
Osteoporosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Interactions of interleukin-6 promoter polymorphisms with dietary and lifestyle factors and their association with bone mass in men and women from the Framingham Osteoporosis Study.
|
15005841 |
2004 |
|
Osteoporosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Moreover, IL-6 is a pathophysiological factor in several hyperproliferative diseases and the paraneoplastic syndromes that often accompany cancer, such as cachexia and osteoporosis; thus, anti-IL-6 therapy would be useful in treating these entities as well.
|
16083340 |
2005 |
|
Osteoporosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Osteoprotegerin (OPG, TNFRSF11B) and interleukin-6 (IL-6, IL6) are putative target genes for estrogen signaling and have been implicated in both cardiovascular diseases and osteoporosis.
|
17878722 |
2007 |
|
Osteoporosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our data showed that TNF-α and IL-6 polymorphisms were associated with overall and site-specific OST in both sexes, and that these associations were dependent on rs1805096 and rs1892534 genotypes of LEPR.
|
27401061 |
2016 |
|
Osteoporosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that genetic variation in or near the IL6 locus may be involved in the etiology of obesity and osteoporosis.
|
12898289 |
2003 |
|
Osteoporosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our results suggested that the C allele of rs1800796 and the C allele of rs2069849 of IL-6 gene interaction between rs1800796 and abdominal obesity were all associated with increased OST risk.
|
31301734 |
2019 |